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Background/Purpose: Heart failure (HF) is the most common cause of hospitalization at medical clinics
for patients older than 65 years.
Purpose: To study the prognostic value of biomarkers, comorbidities, and veriﬁed HF diagnosis for all-
cause and cardiovascular hospitalizations.
Methods: Between 2000 and 2003, 170 patients with HF symptoms according to their general practi-
tioners were recruited and referred for echocardiography, biomarker measures and a ﬁnal cardiology
consultation. HF diagnosis was based on the general practitioner's prespeciﬁed HF record, echocardi-
ography, and hospital records. Records from the departments of medicine and surgery were used to
identify hospitalizations. This is a 10-year longitudinal observational primary healthcare center study.
Results: During 10 years, 136 (80%) patients had 660 and 207 all-cause and cardiovascular hospi-
talizations, respectively. In multivariable logistic regression, age [odds ratio (OR) ¼ 1.1, 95% conﬁ-
dence interval (CI) ¼ 1.01e1.15] and underlying heart disease (OR ¼ 3.5, 95% CI ¼ 1.00e11.89)
signiﬁcantly predicted all-cause hospitalization. Age (OR ¼ 1.1, 95% CI ¼ 1.01e1.12), underlying heart
disease (OR ¼ 3.4, 95% CI ¼ 1.041e1.40), and N-terminal of prohormone brain natriuretic
peptide  800 ng/L (OR ¼ 4.3, 95% CI ¼ 1.5e12.50) signiﬁcantly predicted cardiovascular hospitali-
zations. In Cox regression analysis, overall HF (HR ¼ 1.8, 95% CI ¼ 1.06e2.94) signiﬁcantly predicted
time to ﬁrst all-cause hospitalizations while no variable independently predicted time to ﬁrst car-
diovascular hospitalization.
Conclusion: In patients with HF symptoms managed in primary healthcare, age, and underlying heart
diseases predicted all-cause hospitalizations. N-terminal of prohormone brain natriuretic peptide added
independent prognostic information for cardiovascular hospitalizations.
Copyright © 2016, Asia Paciﬁc League of Clinical Gerontology & Geriatrics. Published by Elsevier Taiwan
LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
Chronicheart failure (HF)occurs in10e20%of thepopulationaged
70e80 years.1 The prognosis is poor for patients with HF, and the
need for hospitalization is frequent2; indeed, HF is themost common
cause for hospitalization at medical clinics for patients older than
65 years.3 In primary healthcare (PHC), elderly patients often have
serious comorbidities, and the contributions of these problems to
hospitalizations of patients with HF are often overlooked.4ent of Medicine, Skellefteå
).
inical Gerontology & Geriatrics. Pub
d/4.0/).The need for markers or other instruments to identify patients
at high risk for hospitalization therefore is urgent. Natriuretic
peptides [N-terminal pro-hormone of brain natriuretic peptide
(NTproBNP)] are relatively new markers for excluding the diag-
nosis5 of HF but also serve as prognostic tools for mortality in pa-
tients with HF.6 The question remains of whether these markers
also can be used to predict hospitalizations. Another marker is
high-sensitivity C-reactive protein (hsCRP), which indicates the
grade of inﬂammation and also predicts cardiovascular diseases.7
Its value for predicting hospitalization in elderly patients with HF
is unknown, however. Reduced kidney function is related to mor-
tality in patients with heart disease,8 and creatinine or estimated
glomerular ﬁltration rate (eGFR) may be expected to be markers oflished by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
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those for HF, including breathlessness and tiredness, and anemia is
rather common in patients with HF but not as well studied when it
comes to predicting the need for hospitalizations in elderly pa-
tients.9 Cholesterol is a well-known risk factor for ischemic heart
disease, especially in younger andmiddle-aged patients, but its role
as a predictive factor for hospitalization in elderly patients with or
without HF is unclear.
We hypothesized that these biomarkers and comorbidities
could have the potential to independently predict all-cause or
cardiovascular-related hospitalization in patients with clinical
symptoms of HF. Thus, our aim with this study was to evaluate the
prognostic value of biomarkers (NTproBNP, creatinine, eGFR, he-
moglobin, hsCRP, and cholesterol), comorbidities and a veriﬁed
diagnosis of HF for all-cause and cardiovascular hospitalizations.
2. Methods
2.1. Study population
The study population and diagnostic procedures with catego-
rization of HF patients have been described in detail previously.10 In
short, between the years 2000 and 2003, 170 patients with clinical
symptoms of HF were recruited from one selected PHC with a
catchment population of 7800 in the northern Sweden. The PHC
had a computer-based registry for patients with a diagnosis of
clinical symptoms of HF. This study comprises patients from the
registry as well as consecutive patients who were identiﬁed by the
general practitioner (GP). All patients had symptoms, essentially
breathlessness, that in the GP's clinical judgment could be caused
by chronic HF.
The GP registered data from the examination of the patient into
a prespeciﬁed HF record. Patients then were referred for an echo-
cardiography (performed by M.O.) and subsequent cardiovascular
consultation. The study cardiologist (K.B.) conﬁrmed or refuted the
diagnosis of HF according to European Society of Cardiology
guidelines11 based on the GP's prespeciﬁed HF record, echocardi-
ography results and hospital records. Underlying heart disease
included patients with myocardial infarction, hypertension, atrial
ﬁbrillation (AF), ischemic heart disease, angina pectoris, and those
with a cardiac murmur as a proxy for valvular disease (8 patients
with mitral insufﬁciency, 4 with aortic stenosis, and 3 with aortic
insufﬁciency; 11 patients had unspeciﬁed cardiac murmurs).
AF was veriﬁed by an electrocardiogram analysis. The diagnosis
of HF was validated with echocardiography. No other clinical vari-
ables were validated. There were missing values for smoker, or ex-
smoker (n¼ 12), and alcohol (n¼ 17). All other categorical variables
were classiﬁed as yes or no.
2.2. Biomarkers
For administrative reasons, blood samples for NTproBNP and
hsCRPwere taken in 159 patients. Blood sampling took place before
the echocardiographic examination from fasting patients who had
rested for 20 minutes. After 5 minutes, the samples were centri-
fuged (1500e2000  g) for 10 minutes at 4C then stored frozen
at 70C.
For analysis of hsCRP, a solid-phase, chemiluminescent immu-
nometric assay (Immulite Analyzer; Diagnostic Products Corpora-
tion, Los Angeles, CA, USA) was used.12 NTproBNP was analyzed
using the Roche Elecsys proBNP immunoassay.13 There is no general
consensus on the best cut-off value for NTproBNP to predict hos-
pitalizations, and different values have been suggested14e16
depending on the clinical setting (e.g., emergency departments or
PHC centres). Our cutoff level for NTproBNP of  800 ng/L was anestimated mean value for clinical purposes based on ﬁndings from
three studies.14e16
The results for creatinine, hemoglobin, and cholesterol analyses
were collected from the GP's pre-speciﬁed HF record. The eGFR was
calculated with the equation from the Modiﬁcation of Diet in Renal
Disease study.17
2.3. Outcome classiﬁcation
To register hospitalizations for 10 years of follow-up, medical
records at the Medical and Surgical Departments in Skellefteå
County Hospital, Skellefteå, Sweden were used. Classiﬁcation was
deﬁned according to ICD-10 for all-cause and cardiovascular hos-
pitalization diagnoses (I00eI99 and transitory ischemic attack,
G45.9).
2.4. Statistical analysis
Baseline characteristics are presented as frequencies or means
and standard deviations. Chi-square and Fisher's exact tests were
used for categorical variables. The association between baseline
characteristics and hospitalizations for 10 years of follow-up was
analyzed with logistic regression analysis and time to ﬁrst hospi-
talizationwith Cox regression analysis. In multivariable logistic and
Cox regression analyses, the categorical variable NTproBNP 
800 ng/L was used instead of the continuous variable.
We used two different models for multivariable logistic or Cox
regression analyses. Model 1 included age and sex as ﬁxed cova-
riates and those variables that signiﬁcantly (p < 0.05) predicted
hospitalizations in univariable analysis. Model 2 tested all variables
from model 1 and with the addition of overall HF compared to
those with no HF. The results are presented as an odds ratio (OR)
and hazard ratio (HR) with the 95% conﬁdence interval (CI). The
assumption of proportional hazard was checked graphically using
KaplaneMeier survival curves for time to ﬁrst hospitalization.
PASW statistics, (SPSS Inc., Chicago, USA) version 18.0, was used for
all statistical analyses.
Patients signed written informed consent for inclusion in the
study. The study was approved by the Committee of Ethics at Umeå
University, Umeå, Sweden (diary number 00-276).
3. Results
3.1. At 10 years of follow-up
A total of 136 of 170 (80%) patients were hospitalized for any
reason, 90 (53%) for cardiovascular causes; see baseline character-
istics in Table 1. In total, there were 660 all-cause hospitalizations
and 207 hospitalizations for cardiovascular reasons. A total of 25
patients (18%) had only one hospitalization, and all others had two
or more. Of special note, all patients with AF had at least one all-
cause hospitalization. The most common cause of hospitalization
was cardiovascular disease (Figure 1). Of 77 patients (84%) with
overall HF, 65 contributed to 351 all-cause hospitalizations, and 46
patients out of 77 (60%) with overall HF accounted for 127 hospi-
talizations due to cardiovascular diseases. The mean number of
hospitalizations/patient did not differ signiﬁcantly between pa-
tients with overall HF and no HF (4.56 ± 4.53 vs. 3.15 ± 3.53,
p ¼ 0.064) for all-cause hospitalization or between overall HF and
no HF (1.65 ± 2.51 vs. 0.88 ± 1.31, p ¼ 0.052) for cardiovascular
hospitalization.
The proportion of patients with HF compared to patients
without HF did not differ signiﬁcantly for being hospitalized for all-
cause (84% vs. 79%, p > 0.05) or for cardiovascular reasons (60% vs.
46%, p > 0.05).
Table 1
Baseline characteristics of 136 patients' hospitalized and 34 patients not hospital-
ized patients at 10 years of follow-up.
Variables n Hospitalized Not
hospitalized
Age (y) 170 78 ± 7.8 74 ± 9.2
Female 121 92 (76) 29 (24)
Male 49 44 (90) 5 (10)
Weight (kg) 162 75 ± 14.3 69 ± 18.4
Smoker or ex-smoker 38 31 (82) 7 (18)
History of alcohol 34 26 (76) 8 (24)
Systolic blood pressure 118 149 ± 25.6 149 ± 23.3
Diastolic blood pressure 117 82 ± 12.2 83 ± 10.1
Heart rate 144 73 ± 14.2 70 ± 16.3
History diabetes 20 19 (95) 1(5)
History angina pectoris 48 42 (88) 6 (12)
History ischemic heart disease 24 22 (92) 2 (8)
History hypertension 69 57 (83) 12 (17)
History myocardial infarction 33 29 (88) 4 (12)
History atrial ﬁbrillation 23 23 (100) 0 (0)
History cardiac murmur 26 21 (81) 5 (19)
History stroke 20 17 (85) 3 (15)
History pulmonary disease 20 16 (80) 4 (20)
Renal impairment
(creatinine > 100)
39 35 (90) 4 (10)
History underlying heart disease 139 117 (84) 22 (16)
Overall HF (systolic and/or
diastolic HF)
77 65 (84) 12 (16)
NTproBNP (ng/L) 159 1252 ± 2951 427 ± 694
NTproBNP  800 ng/L 42 39 (93) 3 (7)
Hemoglobin (g/L) 160 136.3 ± 12.2 135.9 ± 16.8
Hemoglobin < 115 g/L 14 11 (79) 3 (27)
Cholesterol (mM) 150 5.4 ± 1.1 5.9 ± 1.1
Cholesterol < 5.2mM 52 47 (90) 5 (10)
Creatinine (mM) 163 89.2 ± 21.6 81.0 ± 19.3
eGFR (mL/min/1.73 m2) 163 61.9 ± 15.0 66.1 ± 14.3
eGFR  60 mL/min/1.73 m2 74 65 (89) 9 (12)
hsCRP, mg/L 157 6.0 ± 8.7 3.5 ± 5.1
hsCRP > 3 mg/L 65 55 (85) 10 (15)
ACE inhibitor/ARB 46 38 (83) 8 (17)
BB 67 53 (79) 14 (21)
Furosemide 81 69 (85) 12 (15)
Digitalis 14 13 (93) 1 (7)
Potassium sparing 28 24 (86) 4 (14)
ACE & BB or ARB & BB 24 19 (79) 5 (21)
Data are presented as mean (standard deviation) or n (%).
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin II receptor blocker;
BB ¼ b-blocker; eGFR ¼ estimated glomerular ﬁltration rate; HF ¼ heart failure;
hsCRP ¼ high-sensitivity C-reactive protein; NTproBNP ¼ N-terminal prohormone
of brain natriuretic peptide.
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Figure 1. Distribution of all-cause hospitalizations, 207 cardiovascular and 454 noncardiova
follow-up.
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In logistic regression univariable analysis, age, male sex, AF,
underlying heart disease, NTproBNP 800 ng/L and eGFR 60 mL/
min/1.73 m2 were signiﬁcantly associated with all-cause hospital-
ization during 10 years of follow-up (Table 2).
In multivariable model 1, after the addition of age and sex, age
and male sex remained signiﬁcantly associated with risk for all-
cause hospitalization. In multivariable model 2, after adjustment
also for overall HF, age and underlying heart disease remained
signiﬁcantly associated with all-cause hospitalization (Table 3). In
univariable Cox regression analysis for time to ﬁrst all-cause hos-
pitalization, NTproBNP as the continuous variable (HR ¼ 1.02, 95%
CI ¼ 1.01e1.02) and dichotomized variable ( 800 ng/L; HR ¼ 2.1,
95% CI ¼ 1.43e3.13), hemoglobin (HR ¼ 0.98, 95% CI ¼ 0.96e0.99),
continuous hsCRP (HR ¼ 1.03, 95% CI ¼ 1.01e1.05), cardiac murmur
(HR ¼ 1.7, 95% CI ¼ 1.03e2.65), and overall HF (HR ¼ 2.4, 95%
CI ¼ 1.60e3.53) were signiﬁcantly associated with time to ﬁrst all-
cause hospitalization.
In multivariable Cox regression analysis model 1, NTproBNP 
800 ng/L (HR ¼ 1.7, 95% CI ¼ 1.08e2.60) and hemoglobin
(HR ¼ 0.98, 95% CI ¼ 0.97e0.998) remained signiﬁcantly associated
with all-cause hospitalization. In multivariable model 2, after the
addition of overall HF, only overall HF remained signiﬁcant
(HR ¼ 1.8, 95% CI ¼ 1.06e2.93) (Figure 2).3.3. Cardiovascular hospitalization at 10 years of follow-up
In univariable logistic regression analysis, age, diabetes, AF,
underlying heart disease, and NTproBNP  800 ng/L were signiﬁ-
cantly associated with cardiovascular hospitalization (Table 2).
In multivariable model 1, age and NTproBNP  800 ng/L
remained signiﬁcantly associated with cardiovascular hospitaliza-
tion. In multivariable model 2, age, underlying heart disease and
NTproBNP 800 ng/L remained signiﬁcant (Table 4).
In univariable Cox regression analysis, NTproBNP as a contin-
uous (HR ¼ 1.02, 95% CI ¼ 1.01e1.02) and dichotomized variable (
800 ng/L; HR ¼ 2.3, 95% CI ¼ 1.23e4.17) along with creatinine
(HR ¼ 1.01, 95% CI ¼ 1.00e1.03), hsCRP (HR ¼ 1.04, 95%
CI¼ 1.00e1.08), and overall HF (HR¼ 2.4, 95% CI¼ 1.26e4.50) were
signiﬁcantly associated with time to ﬁrst cardiovascular hospitali-
zation. In multivariable models 1 and 2, when age, sex, and overall200 250
ns
ion, n (%)
Cardiovascular, n = 204
Symptoms, signs not
classified, n = 101
Injury, intoxication, n = 72
Respiratory, n = 55
Musculoskeletal, n = 41
Cancer, n = 39
Digestive, n = 28
Urinary, n = 26
Psychiatric, n = 25
Infection, n = 19
Endocrine, n = 14
Other, n = 36
204 (31)
scular causes in 170 patients with clinical symptoms of heart failure during 10 years of
Table 2
Univariate logistic regression analysis in patients with clinical symptoms of heart failure at 10 years of follow-up.
All-cause hospitalization Cardiovascular hospitalization
OR 95% CI p OR 95% CI p
Age 1.06 1.02e1.11 0.009 1.06 1.02e1.10 0.005
Male 2.77 1.01e7.65 0.049 1.61 0.82e3.16 0.170
Weight 1.03 1.00e1.06 0.051 1.00 0.98e1.02 0.874
Smoker or ex-smoker 1.23 0.48e3.10 0.668 1.38 0.66e2.87 0.397
Alcohol 0.78 0.31e1.94 0.592 0.89 0.42e1.91 0.762
Systolic blood pressure 1.00 0.98e1.02 0.933 1.00 0.99e1.14 0.625
Diastolic blood pressure 0.99 0.95e1.04 0.992 0.99 0.96e1.02 0.617
Heart rate 1.01 0.98e1.04 0.390 1.01 0.98e1.03 0.649
History diabetes 5.36 0.69e41.53 0.108 3.00 1.04e8.67 0.043
Angina pectoris 2.09 0.80e5.41 0.131 1.95 0.98e3.88 0.058
Ischemic heart disease 3.09 0.69e13.83 0.141 1.95 0.78e4.83 0.151
History hypertension 1.32 0.61e2.89 0.483 1.05 0.57e1.93 0.883
History myocardial infarction 2.03 0.66e2.24 0.215 1.47 0.68e3.20 0.327
History atrial ﬁbrillationa N/A N/A 0.004 3.75 1.32e10.63 0.013
History cardiac murmur 1.06 0.37e3.05 0.915 2.25 0.92e5.50 0.076
History stroke 1.48 0.41e5.36 0.554 1.39 0.54e3.58 0.502
History pulmonary disease 1.00 0.31e3.21 1.000 1.10 0.43e2.81 0.844
History renal disease (creatinine >100) 2.67 0.88e8.15 0.084 1.91 0.91e4.00 0.089
History underlying heart disease 3.36 1.43e7.89 0.005 3.41 1.47e7.95 0.004
Overall HF (systolic and/or diastolic HF) 1.43 0.61e3.36 0.410 1.72 0.89e3.34 0.107
NTproBNP (ng/L; divided 100 ng/L) 1.05 0.99e1.13 0.129 1.04 1.01e1.09 0.026
NTproBNP  800 ng/L 4.09 1.17e14.76 0.027 5.50 2.35e12.90 <0.001
Hemoglobin (g/L) 1.00 0.97e1.03 0.888 0.99 0.97e1.01 0.420
Hemoglobin < 115 g/L 0.87 0.23e3.23 0.839 1.66 0.53e5.19 0.385
Cholesterol (mM) 0.73 0.51e1.05 0.089 1.00 0.75e1.33 0.990
Cholesterol < 5.2mM 2.72 0.97e7.68 0.058 1.08 0.55e2.11 0.833
Creatinine (mM) 1.02 1.00e1.04 0.051 1.01 0.996e1.03 0.150
eGFR (mL/min/1.73 m2) 0.98 0.96e1.01 0.148 0.99 0.97e1.01 0.309
eGFR 60 mL/min/1.73 m2 2.67 1.15e6.18 0.022 1.27 0.68e2.36 0.448
hsCRP (mg/L) 1.06 0.98e1.14 0.154 1.01 0.97e1.05 0.732
hsCRP > 3 mg/L 1.63 0.71e3.74 0.251 1.47 0.78e2.49 0.239
ACE inhibitor/AII-blocker (ARB) 1.26 0.53e2.03 0.605 1.38 0.69e2.73 0.361
BB 0.91 0.42e1.96 0.814 1.29 0.69e2.39 0.427
Furosemide 1.89 0.87e4.12 0.110 1.22 0.67e2.24 0.515
Digitalis 3.49 0.44e27.64 0.237 2.38 0.71e7.90 0.158
Potassium sparing 1.61 0.52e4.99 0.412 1.75 0.76e4.05 0.192
ACE and BB or ARB and BB 0.94 0.32e2.73 0.912 2.85 0.74e10.93 0.126
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin II receptor blocker; BB ¼ b-blocker; CI ¼ conﬁdence interval; eGFR ¼ estimated glomerular ﬁltration rate;
HF ¼ heart failure; hsCRP ¼ high-sensitivity C-reactive protein; NTproBNP ¼ N-terminal prohormone of brain natriuretic peptide; OR ¼ odds ratio.
a Atrial ﬁbrillation was tested with Fisher's exact test for all-cause hospitalization.
Table 3
Multivariate logistic regression analysis for all-cause hospitalization at 10 years of follow-up in patients with clinical symptoms of heart failure.
Variables Model 1a, n ¼ 152 Model 2b, n ¼ 128
OR 95% CI p OR 95% CI p
Age 1.1 1.01e1.12 0.023 1.1 1.01e1.15 0.024
Male sex 3.4 1.05e10.85 0.041 3.3 0.87e12.15 0.081
History underlying heart disease 2.5 0.94e6.54 0.067 3.5 1.00e11.89 0.049
NTproBNP  800 ng/L 2.4 0.63e8.78 0.202 1.9 0.44e8.20 0.392
eGFR  60 mL/min/1.73 m2 1.7 0.65e4.31 0.289 1.7 0.56e5.19 0.350
Overall HF (systolic &/or diastolic HF) 0.7 0.23e2.18 0.548
CI ¼ conﬁdence interval; eGFR ¼ estimated glomerular ﬁltration rate; HF ¼ heart failure; OR ¼ odds ratio; NTproBNP ¼ N-terminal prohormone of brain natriuretic peptide.
a Age and sex and signiﬁcant variables from the univariate analysis.
b All variables from Model 1 and addition of overall HF.
M. Olofsson et al. / Journal of Clinical Gerontology & Geriatrics 7 (2016) 53e5956HF were added, none of the variables in the multivariable analysis
remained signiﬁcant.
4. Discussion
Our main ﬁndings were that age and underlying heart disease
signiﬁcantly predicted all-cause hospitalization in multivariable
analysis. In addition, overall HF independently predicted time to
ﬁrst all-cause hospitalization. By contrast, NTproBNP  800 ng/L,
elevated creatinine, elevated hsCRP, and overall HF were signiﬁ-
cantly associated with time to ﬁrst cardiovascular hospitalization,
but only in the univariable analysis.An epidemiologic study from Olmsted County18 comprising
1077 patients with HF and with a mean follow-up of 4.7 years (our
study: 6.4 years of mean follow-up) demonstrated that 83% of their
patients had at least one hospitalization. Their patients were in the
same age range as ours, but they all had HF. Our patients had sus-
pected HF, and 80% were still hospitalized. As in our study, those
authors found that the majority of hospitalizations were due to
noncardiovascular causes. Their univariable risk factors for all-
cause hospitalizations were age, male sex, hypertension, diabetes,
chronic obstructive pulmonary disease, anemia, and creatinine
clearance < 30 mL/min, which was somewhat similar to our ﬁnd-
ings except for diabetes and chronic obstructive pulmonary disease.
Figure 2. Cox regression analysis with hazard ratio (HR) and conﬁdence interval (CI) for time to ﬁrst all-cause hospitalization in patients with overall heart failure (HF) compared to
patients without HF after adjustment for age, sex, NTproBNP >800 ng/L, hemoglobin, and CRP (model 2). CRP ¼ C-reactive protein; NTproBNP ¼ N-terminal pro-hormone of brain
natriuretic peptide.
Table 4
Multivariate logistic regression analysis for cardiovascular hospitalization at 10 years of follow-up in patients with clinical symptoms of heart failure.
Variables Model 1a, n ¼ 159 Model 2b, n ¼ 133
OR 95% CI p OR 95% CI p
Age 1.1 1.01e1.11 0.014 1.1 1.01e1.12 0.030
Male 1.7 0.74e3.73 0.220 1.2 0.49e2.95 0.696
History diabetes 2.3 0.74e7.15 0.151 2.4 0.73e7.91 0.148
History underlying heart disease 2.5 0.99e6.18 0.050 3.4 1.04e11.40 0.044
NTproBNP  800 ng/L 3.6 1.47e8.87 0.005 4.3 1.50e12.50 0.007
Overall HF (systolic &/or diastolic HF) 0.9 0.36e2.03 0.716
CI ¼ conﬁdence interval; HF ¼ heart failure; NTproBNP ¼ N-terminal prohormone of brain natriuretic peptide; OR ¼ odds ratio.
a age and sex and signiﬁcant variables from the univariate analysis; b, all variables from Model 1 and addition of overall HF.
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it comes to risk for time to ﬁrst hospitalization. In a survey on HF-
related hospitalizations in the USA between 1979 and 2004, Fang
et al19 reported increasing admissions to the hospital with
increasing age. They emphasized the importance of treating
noncardiac conditions in patients with HF to decrease hospitali-
zations. By contrast, a registry study from Sweden between the
years 1987 and 200620 on patients with a diagnosis of HF revealed
another pattern of increasing admission to the hospital for younger
(< 45 years) patients with HF while in patients aged 54e84 years,
hospitalizations peaked in the 1990s but then decreased.
Our ﬁndings highlight the importance of identifying underlying
heart disease because these patients were included due to a sus-
picion of HF. In these older patients, there was an association not
only with cardiovascular hospitalization but more importantly also
with all-cause hospitalization, suggesting a fragility of these
patients to which comorbidities beyond heart diseases may havecontributed. Of special note, all patients with AF had at least one all-
cause hospitalization, which calls attention to this disorder with
regard to both rate and rhythm control as well as anticoagulation
considerations.21
Studies are lacking on the prognostic importance of cardiac
murmurs in PHC. A study from Copenhagen22 showed that in
hospitalized unselected patients, a murmur was present in 22% and
increased the risk of 1-year mortality after adjustment for age and
sex, but there was no information about whether a murmur was
associated with a risk for re-hospitalization. Our study extends the
present knowledge, with 15% of hospitalized patients having a
cardiac murmur and 80% of these patients hospitalized at 10 years
of follow-up. The authors of the Copenhagen study also pointed out
the importance of heart auscultation for noncardiologists and
concluded that detection of a murmur in an elderly person
admitted to the hospital is strongly prognostic. In our study, cardiac
murmur at the PHC also seemed to be of value to predict time to
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the clinical value of cardiac auscultation even in the present era of
new modern technologies of biomarkers and echocardiography. In
a study by Adlbrecht et al,23 1203 primary care patients were
screened to evaluate the predictive value of NTproBNP for time to
ﬁrst all-cause hospitalization with 12 months of follow-up. That
study included patients with hypertension, diabetes mellitus, cor-
onary artery disease or suspected HF and showed that NTproBNP
was an independent predictor for time to all-cause hospitalization.
In our study, both NTproBNP and underlying heart disease were
independent predictors for cardiovascular hospitalization; how-
ever, our patients were comparatively older, and the follow-up time
was much longer.
High levels of hsCRP have been shown to predict time to ﬁrst
hospitalization for patients with HF.24 Compared to our patients,
the patients in the previous report were much younger, having a
mean age of 63 years. Low cholesterol is a known predictor for
mortality but also for re-hospitalization25 in elderly patients hos-
pitalized with HF, but we found no association for hospitalization in
our study. A systematic review by Damman et al26 on patients with
HF demonstrated that worsening renal function (deﬁned as an in-
crease in serum creatinine of > 26.5mM) was associated with a
modest increase in the rate of all-cause hospitalization. In our
study, impaired renal function deﬁned as eGFR  60 mL/min/
1.73 m2 was associated with all-cause hospitalization and elevated
serum creatinine levels with time to ﬁrst cardiovascular hospitali-
zation, but only in univariable analysis.
4.1. Clinical implications
Our study adds the following clinical information to be
considered in the management of elderly patients in PHC with
clinical symptoms of HF and a risk for future hospitalization: First is
the importance of registering the underlying heart disease(s) with
special attention to AF; second is the importance of diagnosing the
presence of HF and taking elevated NTproBNP into account; and
third is examining and validating cardiac murmurs in the patients.
The above suggestions need to be tested in future prospective
studies with clearly validated heart diseases. Moreover, our cutoff
value for NTproBNP should be regarded as exploratory, and further
prospective studies are needed to identify the most accurate cutoff
value to predict hospitalizations in elderly patients in primary
healthcare. Larger studies are also needed to identify other bio-
markers as additional prognostic tools.
4.2. Strengths and limitations
The strength of the present study is the long-term follow-up in a
rather unselected group of patients with clinical symptoms of HF.
The diagnosis of HF was validated with echocardiography. Our
study has a number of limitations, however. First, it is a single-
center study, and the study population is limited. Second, data for
clinical variables except for HF and AFwere not validated. The levels
of creatinine, hemoglobin, and cholesterol were registered from the
GP's prespeciﬁed HF record. Some data for clinical variables were
missing for unknown reasons. For underlying heart diseases,
missing data were regarded as absence of disease.
Another limitation is that the number of patients in Tables 3 and
4 differ compared to the number in Table 1. Comparedwith baseline
characteristics for all 170 patients, age, sex, underlying heart dis-
ease, diabetes, overall heart failure, NTproBNP, and eGFR did not
differ signiﬁcantly in mean values or proportions among the pa-
tients presented in Tables 3 and 4. This suggests that patients in
Tables 3 and 4 share almost the same characteristics as all 170
patients.We realize that the limited number of patients and hospitali-
zations may have introduced a type 2 error that could limit the full
understanding of the real value of our studied biomarkers for
hospitalizations in elderly patients. Elevated hsCRP, a high level of
creatinine and low hemoglobin were all signiﬁcant in univariable
analysis for time to ﬁrst hospitalization, suggesting that they may
have a predictive value, but this possibility needs to be conﬁrmed in
larger studies.
5. Conclusion
In this long-term follow-up study in patients with clinical
symptoms of HF managed in PHC, age, and underlying heart dis-
eases were predictors for hospitalization. Special attention should
be paid to AF because all patients with this condition were hospi-
talized. Cox regression demonstrated that patients with HF were at
greater risk for all-cause hospitalization compared to thosewithout
HF. High NTproBNP added further independent prognostic infor-
mation about risk for cardiovascular hospitalizations. No other
studied biomarker contributed to prediction of all-cause or car-
diovascular hospitalizations.
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